TOCCA Life Holdings, Inc. (TLIF) 株価パフォーマンス
TOCCA Life Holdings, Inc.の財務実績を確認します。内容には、時価総額、価格変動率、株価収益率、および過去と現在の株価が含まれます。
前日終値0.00
52週高値0.01
開く0.00
52週安値0.00
資金フロー0.00%
PER0%
T/O0.00b
PBR0%
離職率0.00%
時価総額0.01b
配当0
総株式数3.19b
配当利回り0%
ロットサイズ1
TOCCA Life Holdings, Inc.会社紹介
The Company has had several business models throughout its organizational history. In January 2015, change in control of the Company occurred and as a result a new business model was adopted. The Company, through it's subsidiary Xirxi Co., Ltd, a British Virgin Islands corporation with offices in Bangkok and Thaliand ("Xirxi"), is a business-to-consumer and business-to-business ecommerce company in Asia. It is expected that operations through this subsidiary will be winding down in order for the Company to concentrate all of its efforts into the business model of it's other subsidiary TOCCA Life Coaching, Inc.
In focusing on its new business model, TOCCA Life Holdings, Inc., through its subsidiary TOCCA Life Coaching, Inc., a Florida corporation, offers structured sober living residences and prescribed clinical laboratory toxicology testing while providing the general public informative detection practices and products for the early detection of the disease of addiction.
TOCCA Life Coaching, Inc. is in the process of organizing and systematizing sober living residences in the South Florida area initially and then expanding nationally through internal growth and acquisitions which will capture the inherent 500% gross land lord tenant margins while complementing the network with a state of the art laboratory that provides illicit and prescribed drug monitoring. The clinical toxicology services to monitor drug use can exponentially escalate gross profit margins with anticipated average revenues of $700 per test per client up to 3 times per week on a reoccurring basis as prescribed by doctors to ensure the clients' accountability while living in the residence, providing a safe residence for clients and safe work environment for staff. The anticipated revenues are inclusive and post revenue share agreement costs which finance the laboratories in part.